Gülşah Bayraktar

Dr. Gülşah Bayraktar

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2013 in European Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
MPMichaela Prinz
Michaela Prinz
SPSülünay Parlar
Sülünay Parlar
GBGülşah Bayraktar
Gülşah Bayraktar
VAVildan Alptüzün
Vildan Alptüzün
EEErcin Erciyas
Ercin Erciyas
UHUlrike Holzgrabe
Ulrike Holzgrabe

2 June 2020 in Archiv der Pharmazie
Verified
Journal Article
Closed access
PDF file
huseyin istanbulluhuseyin istanbullu
huseyin istanbullu
GBGülşah Bayraktar
Gülşah Bayraktar
HAHasan Akbaba
Hasan Akbaba
ICIbrahim Cavus
Ibrahim Cavus
GCGunes Coban
Gunes Coban
EEErcin Erciyas
Ercin Erciyas

1 January 2016 in Chemical and Pharmaceutical Bulletin
Verified
Journal Article
Open access
PDF file
SPSulunay Parlar
Sulunay Parlar
GBGülşah Bayraktar
Gülşah Bayraktar
ATAyse Hande Tarikogullari
Ayse Hande Tarikogullari
VAVildan Alptüzün
Vildan Alptüzün
EEErcin Erciyas
Ercin Erciyas
A series of pyridinium salts bearing alkylphenyl groups at 1 position and hydrazone structure at 4 position of the pyridinium ring were synthesized and evaluated for the inhibition of both acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) enzymes. The cholinesterase (ChE) inhibitory activity studies were carried out by using the Ellman’s colorimetric method. All compounds displayed considerable AChE and BuChE inhibitory activity and some of the compounds manifested remarkable anti-AChE activity compared to the reference compound, galantamine. Among the title compounds, the series including benzofuran aromatic ring exhibited the best inhibitory activity both on AChE and BuChE enzymes. Compound 3b, 4-[2-(1-(benzofuran-2-yl)ethylidene)hydrazinyl]-1-(3-phenylpropyl)pyridinium bromide, was the most active compound with IC50 value of 0.23 (0.24) µM against enantiomeric excess (ee)AChE (human (h)AChE) while compound 3a, 4-[2-(1-(benzofuran-2-yl)ethylidene)hydrazinyl]-1-phenethylpyridinium bromide, was the most active compound with IC50 value of 0.95 µM against BuChE. Moreover, 3a and b exhibited higher activity than the reference compound galantamine (eeAChE (hAChE) IC50 0.43 (0.52) µM; BuChE IC50 14.92 µM). Molecular docking studies were carried out on 3b having highest inhibitory activity against AChE.

23 December 2022 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
huseyin istanbulluhuseyin istanbullu
huseyin istanbullu
GBGülşah Bayraktar
Gülşah Bayraktar
GKGulsah Karakaya
Gulsah Karakaya
HAHasan Akbaba
Hasan Akbaba
NPNami Ege Perk
Nami Ege Perk
VAVildan Alptuzun
Vildan Alptuzun

9 April 2024 in Archiv der Pharmazie
Verified
Journal Article
Open access
PDF file
GBGülşah Bayraktar
Gülşah Bayraktar
MBManuela Bartolini
Manuela Bartolini
MBMaria Laura Bolognesi
Maria Laura Bolognesi
MEMumin Alper Erdoğan
Mumin Alper Erdoğan
GAGüliz Armağan
Güliz Armağan
VAVildan Alptüzün
Vildan Alptüzün
A series of tacrine–donepezil hybrids were synthesized as potential multifunctional anti‐Alzheimer's disease (AD) compounds. For this purpose, tacrine and the benzylpiperidine moiety of donepezil were fused with a hydrazone group to achieve a small library of tacrine–donepezil hybrids. In agreement with the design, all compounds showed inhibitory activity toward both acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) with IC50 values in the low micromolar range. Kinetic studies on the most potent cholinesterase (ChE) inhibitors within the series showed a mixed‐type inhibition mechanism on both enzymes. Also, the docking studies indicated that the compounds inhibit ChEs by dual binding site (DBS) interactions. Notably, tacrine–donepezil hybrids also exhibited significant neuroprotection against H2O2‐induced cell death in a differentiated human neuroblastoma (SH‐SY5Y) cell line at concentrations close to their IC50 values on ChEs and showed high to medium blood–brain barrier (BBB) permeability on human cerebral microvascular endothelial cells (HBEC‐5i). Besides, the compounds do not cause remarkable toxicity in a human hepatocellular carcinoma cell line (HepG2) and SH‐SY5Y cells. Additionally, the compounds were predicted to also have good bioavailability. Among the tested compounds, H4, H16, H17, and H24 stand out with their biological profile. Taken together, the proposed novel tacrine–donepezil scaffold represents a promising starting point for the development of novel anti‐ChE multifunctional agents against AD.

9 October 2024 in European Journal of Medicinal Chemistry Reports
Verified
Journal Article
Open access
GBGülşah Bayraktar
Gülşah Bayraktar
Pascal MarchandPascal Marchand
Pascal Marchand
EBEUZEBIO GUIMARAES BARBOSA
EUZEBIO GUIMARAES BARBOSA
MSMarilia Cecilia da Silva
Marilia Cecilia da Silva
KWKaren Cacilda Weber
Karen Cacilda Weber
huseyin istanbulluhuseyin istanbullu
huseyin istanbullu